FDA Approves DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Prasco Laboratories

# FDA Approves Amphetamine Combination Formulation for Prasco Laboratories Prasco Laboratories received FDA approval for its oral amphetamine combination therapy on October 11, 2001, positioning the company to compete in the established attention deficit and narcolepsy treatment market. The approval of the mixed amphetamine salts formulation expands Prasco's portfolio in the central nervous system disorder segment and allows the manufacturer to capture market share in a therapeutic area with substantial patient populations.